Literature DB >> 22941888

The study of risk in pulmonary arterial hypertension.

Lewis J Rubin1, Gerald Simonneau, David Badesch, Nazzareno Galiè, Marc Humbert, Anne Keogh, Joseph Massaro, Marco Matucci Cerinic, Olivier Sitbon, Steven Kymes.   

Abstract

A growing body of published evidence exists on the risk factors for disease progression in pulmonary arterial hypertension (PAH). The Scientific Steering Committee for the Study of Risk in PAH was established to bring together leading clinical and statistical experts in PAH and risk modelling, for the purpose of advancing the understanding of the risk of development and progression of PAH. Herein, we discuss the impact of this information on three key areas: 1) clinical decision-making; 2) policy and reimbursement; and 3) future trials and research.

Entities:  

Mesh：

Year:  2012        PMID： 22941888     DOI： 10.1183/09059180.00003712

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN： 0905-9180


  7 in total

1.  Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension.

Authors:  Lahouaria Hadri; Razmig G Kratlian; Ludovic Benard; Bradley A Maron; Peter Dorfmüller; Dennis Ladage; Christophe Guignabert; Kiyotake Ishikawa; Jaume Aguero; Borja Ibanez; Irene C Turnbull; Erik Kohlbrenner; Lifan Liang; Krisztina Zsebo; Marc Humbert; Jean-Sébastien Hulot; Yoshiaki Kawase; Roger J Hajjar; Jane A Leopold
Journal:  Circulation       Date:  2013-06-26       Impact factor: 29.690

2.  Role of Krüppel-like factor 4 in cigarette smoke-induced pulmonary vascular remodeling.

Authors:  Desheng Sun; Qinghai Li; Dandan Ding; Xiaochen Li; Min Xie; Yongjian Xu; Xiansheng Liu
Journal:  Am J Transl Res       Date:  2018-02-15       Impact factor: 4.060

3.  Short-term improvement in pulmonary hemodynamics is strongly predictive of long-term survival in patients with pulmonary arterial hypertension.

Authors:  Henning Tiede; Natascha Sommer; Katrin Milger; Robert Voswinckel; Dirk Bandorski; Ralph T Schermuly; Norbert Weissmann; Friedrich Grimminger; Werner Seeger; Hossein A Ghofrani
Journal:  Pulm Circ       Date:  2013-11-19       Impact factor: 3.017

Review 4.  The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series).

Authors:  Bradley A Maron; Jane A Leopold
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

5.  Inhalable delivery of AAV-based MRP4/ABCC4 silencing RNA prevents monocrotaline-induced pulmonary hypertension.

Authors:  Caroline Claude; Nathalie Mougenot; Julia Bechaux; Lahouaria Hadri; Damian Brockschnieder; Michel Clergue; Fabrice Atassi; Anne-Marie Lompré; Jean-Sébastien Hulot
Journal:  Mol Ther Methods Clin Dev       Date:  2015-02-04       Impact factor: 6.698

6.  Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition.

Authors:  Maria A Cavasin; Kimberly M Demos-Davies; Katherine B Schuetze; Weston W Blakeslee; Matthew S Stratton; Rubin M Tuder; Timothy A McKinsey
Journal:  J Transl Med       Date:  2014-11-26       Impact factor: 5.531

7.  miR‑760 mediates hypoxia-induced proliferation and apoptosis of human pulmonary artery smooth muscle cells via targeting TLR4.

Authors:  Yu-Zhong Yang; Yun-Feng Zhang; Lei Yang; Jing Xu; Xu-Ming Mo; Wei Peng
Journal:  Int J Mol Med       Date:  2018-09-07       Impact factor: 4.101
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.